BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 20, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Arzerra ofatumumab: Development discontinued

The partners said GlaxoSmithKline will discontinue development of IV ofatumumab for autoimmune indications to instead focus on a subcutaneous formulation. As a result, further enrollment will be discontinued for a Phase III trial of IV ofatumumab in RA. GSK said it believes the subcutaneous...

Read the full 198 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >